Download PDF
Semin Musculoskelet Radiol 2001; 05(2): 183-188
DOI: 10.1055/s-2001-15678
Nuclear Imaging of Bone Tumors

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Nuclear Imaging of Bone Tumors: FDG-PET

Jun Aoki1 , Tomio Inoue2 , Katsumi Tomiyoshi2 , Tetsuya Shinozaki3 , Hideomi Watanabe3 , Kenji Takagishi3 , Keigo Endo1 2
  • 1Department of Diagnostic Radiology, Gunma University School of Medicine, Maebashi, Japan
  • 2Department of Nuclear Medicine, Gunma University School of Medicine, Maebashi, Japan
  • 3Department of Orthopedic Surgery, Gunma University School of Medicine, Maebashi, Japan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Positron emission tomography (PET) has become a very useful adjunct to anatomic imaging techniques, because it can provide an in vivo method for quantifying functional metabolism in normal and diseased tissues. Clinical trials with [18F] 2-deoxy-2-fluoro-D-glucose (FDG), the most commonly used radiolabeled tracer for PET imaging, has demonstrated increased accumulation of FDG in cancer tissue. FDG-PET is now widely used for the detection, differentiation, grading, staging, and monitoring of various neoplasms. However, the significance of FDG-PET in such evaluations of primary bone tumors and tumor-like lesions has not been extensively elucidated. In this article, we present recent advances in FDG-PET studies for evaluating primary bone tumors and tumor-like lesions.

KEYWORD

Bone neoplasms - emission computed tomography (ECT) - glucose

REFERENCES

  • 1 Lodwick G S, Wilson A J, Farrell C, Virtama P, Dittrich F. Determining growth rates of focal lesions of bone from radiographs.  Radiology . 1980;  134 577-583
    CrossrefPubMedGoogle Scholar
  • 2 Hudson T M. Radiologic-Pathologic Correlation of Musculoskeletal Lesions.  Baltimore: Williams & Wilkins 1987: 1-7
    Google Scholar
  • 3 Moser P R, Madewell J E. An approach to primary bone tumors.  Radiol Clin North Am . 1987;  25 1049-1093
    PubMedGoogle Scholar
  • 4 Sundaram M, McGuire M H. Computed tomography or magnetic resonance for evaluating the solitary tumor or tumor-like lesions of bone?.  Skeletal Radiol . 1988;  17 393-401
    CrossrefPubMedGoogle Scholar
  • 5 Dalinka M K, Zlatkin M B, Chao P, Kricum M E, Kressel H Y. The use of magnetic resonance imaging in the evaluation of bone and soft-tissue tumors.  Radiol Clin North Am . 1990;  28 461-470
    PubMedGoogle Scholar
  • 6 Hudson T M, Chew F S, Manaster B J. Scintigraphy of benign exostoses and exostotic chondrosarcomas.  AJR . 1983;  140 581-586
    PubMedGoogle Scholar
  • 7 Vande Streek R P, Carretta R F, Weiland F L. Nuclear medicine approaches to musculoskeletal disease.  Radiol Clin North Am . 1994;  32 227-253
    PubMedGoogle Scholar
  • 8 Strauss L G, Conti P S. The applications of PET in oncology.  J Nucl Med . 1991;  32 623-648
    PubMedGoogle Scholar
  • 9 Hoh C K, Schiepers C, Seltzer M A. PET in oncology: will it replace the other modalities?.  Semin Nucl Med . 1997;  27 94-106
    PubMedGoogle Scholar
  • 10 Brock C S, Meikle S R, Price P. Does fluorine-18 fluorodeoxy glucose metabolic imaging of tumors benefit oncology?.  Eur J Nucl Med . 1997;  24 691-705
    PubMedGoogle Scholar
  • 11 Bar-Shalon R, Valdivia A Y, Blaufox M D. PET imaging in oncology.  Semin Nucl Med . 2000;  30 150-185
    PubMedGoogle Scholar
  • 12 Gallagher B M, Fowler J S, Gutterson N I, MacGregor R R, Wan C, Wolf A P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.  J Nucl Med . 1978;  19 1154-1161
    PubMedGoogle Scholar
  • 13 Kern K A, Brunetti A, Norton J A. Metabolic imaging of human extremity musculoskeletal tumors by PET.  J Nucl Med . 1988;  29 181-186
    PubMedGoogle Scholar
  • 14 Adler L P, Blair H F, Makley J T. Noninvasive grading of musculoskeletal tumors using PET.  J Nucl Med . 1991;  32 1508-1512
    PubMedGoogle Scholar
  • 15 Dehdashti F D, Siegel G A, Griffeth L K. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.  Radiology . 1996;  200 243-247
    PubMedGoogle Scholar
  • 16 Eary J F, Conrad E U, Bruckner J D. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.  Clin Cancer Res . 1998;  4 1215-1220
    PubMedGoogle Scholar
  • 17 Kole A C, Nieweg O E, Hoekstra H J, van Horn R J, Koops H S, Vaalburg. Fluorine-18 fluorodeoxyglucose assessment of glucose metabolism in bone tumors.  J Nucl Med . 1998;  39 810-815
    PubMedGoogle Scholar
  • 18 Johnston J. Giant cell tumor of bone: the role of the giant cell in orthopedic pathology.  Orthop Clin North Am . 1977;  8 751-770
    PubMedGoogle Scholar
  • 19 Ling L, Klein M J, Sissons H A, Steiner G C, Winchester R J. Expression of Ia and monocyte macrophage lineage antigens in giant cell tumor of bone and related lesions.  Arch Pathol Lab Med . 1988;  112 65-69
    PubMedGoogle Scholar
  • 20 Aoki J, Watanabe H, Shinozaki T. FDG-PET of primary benign and malignant bone tumors: SUV in 52 lesions.  Radiology (in press).
    PubMedGoogle Scholar
  • 21 Aoki J, Watanabe H, Shinozaki T. FDG-PET in differential diagnosis and grading of chondrosarcoma.  J Compt Assist Tomogr . 1999;  23 603-608
    PubMedGoogle Scholar
  • 22 Guhlmann A, Brechy-Krauss D, Suger G. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings.  Radiology . 1998;  206 749-754
    CrossrefPubMedGoogle Scholar
  • 23 Palmer W E, Rosenthal D I, Schoenberg O I. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.  Radiology . 1995;  196 647-655
    CrossrefPubMedGoogle Scholar
  • 24 Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18 fluorodeoxyglucose in turpentine-induced inflammatory tissue.  J Nucl Med . 1995;  36 1301-1306
    PubMedGoogle Scholar
  • 25 Enneking W F, Spanier S S, Goodman M A. A system for the surgical staging of musculoskeletal sarcoma.  Clin Orthop . 1980;  153 106-120
    PubMedGoogle Scholar
  • 26 Watanabe H, Inoue T, Shinozaki T. PET imaging of musculoskeletal tumors with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.  Eur J Nucl Med . 2000;  27 1509-1517
    CrossrefPubMedGoogle Scholar
  • 27 Vanel D, Verstraete K L, Shapeero L G. Primary tumors of the musculoskeletal system.  Radiol Clin North Am . 1997;  35 213-237
    PubMedGoogle Scholar
  • 28 Garcia J R, Kim E E, Wong F CL. Comparison of fluorine-18-FDG PET and technetium 99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.  J Nucl Med . 1996;  37 1476-1479
    PubMedGoogle Scholar
  • 29 Kole A C, Nieweg O E, van Ginkel J R. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F] fluorodeoxyglucose.  Ann Surg Oncol . 1997;  4 57-63
    PubMedGoogle Scholar
  • 30 Van Ginkel J R, Hoekstra H J, Pruim J. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.  J Nucl Med . 1996;  37 984-990
    PubMedGoogle Scholar
  • 31 Jones D N, McCowage G B, Sostman H D. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.  J Nucl Med . 1996;  37 1438-1444
    PubMedGoogle Scholar
      >